STOCK TITAN

Esperion to Report First Quarter 2024 Financial Results on May 7

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Esperion (ESPR) will report its first quarter 2024 financial results on May 7, 2024. The company aims to improve outcomes for patients with cardiovascular and cardiometabolic diseases by developing innovative medicines to reduce LDL-cholesterol levels.
Esperion (ESPR) pubblicherà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024. L'azienda mira a migliorare i risultati per i pazienti affetti da malattie cardiovascolari e cardiometaboliche, sviluppando nuovi farmaci per ridurre i livelli di colesterolo LDL.
Esperion (ESPR) reportará sus resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024. La compañía tiene como objetivo mejorar los resultados para pacientes con enfermedades cardiovasculares y cardiometabólicas mediante el desarrollo de medicinas innovadoras para reducir los niveles de colesterol LDL.
에스페리온(ESPR)은 2024년 5월 7일에 2024년 첫 분기 재무 결과를 보고할 예정입니다. 이 회사는 심혈관 및 심장대사 질환을 앓고 있는 환자들의 결과를 개선하기 위해 LDL 콜레스테롤 수치를 낮추는 혁신적인 약물을 개발함으로써 목표를 두고 있습니다.
Esperion (ESPR) publiera ses résultats financiers du premier trimestre 2024 le 7 mai 2024. L'entreprise vise à améliorer les résultats pour les patients souffrant de maladies cardiovasculaires et cardiometaboliques en développant des médicaments innovants pour réduire les niveaux de cholestérol LDL.
Esperion (ESPR) wird am 7. Mai 2024 seine Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen zielt darauf ab, die Ergebnisse für Patienten mit kardiovaskulären und kardiometabolischen Erkrankungen zu verbessern, indem es innovative Medikamente zur Senkung des LDL-Cholesterinspiegels entwickelt.
Positive
  • None.
Negative
  • None.

ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.

A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Esperion Contact Information:
Investors:
Alexis Callahan
investorrelations@esperion.com
(406) 539-1762
  
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438


FAQ

When will Esperion report its first quarter 2024 financial results?

Esperion will report its first quarter 2024 financial results on May 7, 2024.

What time will the webcast to discuss the financial results be held?

The webcast to discuss the financial results will be held at 8:00 a.m. ET.

What is Esperion's focus in developing medicines?

Esperion focuses on developing innovative medicines to help improve outcomes for patients with cardiovascular and cardiometabolic diseases.

How can investors access the webcast replay?

Investors can access the webcast replay on the investor and media section of Esperion's website.

Esperion Therapeutics, Inc.

NASDAQ:ESPR

ESPR Rankings

ESPR Latest News

ESPR Stock Data

476.49M
196.07M
0.5%
66.33%
17.05%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
ANN ARBOR